Abivax SA

Abivax SA's next confirmed earnings release is scheduled for December 14, 2026.

As of June 30, 2026, Abivax SA has 79.82M shares outstanding.

As of June 30, 2026, Abivax SA maintains a current ratio of 5.97, meaning it holds 6.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.33, indicating conservative leverage, while an interest coverage ratio of -42.69 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Abivax SA posted a negative return on equity (ROE) of -40.39, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -31.70, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 69.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Abivax SA recorded an income tax benefit of -5.85M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -171.75M and -165.90M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, Abivax SA generated - - in revenue and converted that into -165.90M in net income, yielding earnings per share of -2.09. EBITDA reached -139.60M, while operating income came in at -140.34M.

As of June 30, 2026, Abivax SA holds 410.68M in cash and equivalents against 1.21M in total debt, resulting in a net debt position of -387.99M. Total book value stands at 366.27M, with working capital of 355.94M providing operational flexibility.

Abivax SA produced -102.51M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -166,000.00 in capital expenditures, free cash flow totaled -102.67M - equivalent to -1.29 per share.